Literature DB >> 24957738

Acute-phase proteins in relation to neuropsychiatric symptoms and use of psychotropic medication in Huntington's disease.

J A Bouwens1, A A M Hubers2, E van Duijn3, C M Cobbaert4, R A C Roos5, R C van der Mast2, E J Giltay2.   

Abstract

Activation of the innate immune system has been postulated in the pathogenesis of Huntington's disease (HD). We studied serum concentrations of C-reactive protein (CRP) and low albumin as positive and negative acute-phase proteins in HD. Multivariate linear and logistic regression was used to study the association between acute-phase protein levels in relation to clinical, neuropsychiatric, cognitive, and psychotropic use characteristics in a cohort consisting of 122 HD mutation carriers and 42 controls at first biomarker measurement, and 85 HD mutation carriers and 32 controls at second biomarker measurement. Significant associations were found between acute-phase protein levels and Total Functioning Capacity (TFC) score, severity of apathy, cognitive impairment, and the use of antipsychotics. Interestingly, all significant results with neuropsychiatric symptoms disappeared after additional adjusting for antipsychotic use. High sensitivity CRP levels were highest and albumin levels were lowest in mutation carriers who continuously used antipsychotics during follow-up versus those that had never used antipsychotics (mean difference for CRP 1.4 SE mg/L; P=0.04; mean difference for albumin 3 SE g/L; P<0.001). The associations found between acute-phase proteins and TFC score, apathy, and cognitive impairment could mainly be attributed to the use of antipsychotics. This study provides evidence that HD mutation carriers who use antipsychotics are prone to develop an acute-phase response.
Copyright © 2014 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Acute-phase proteins; Antipsychotics; Huntington׳s disease; Neuropsychiatric symptoms; Psychotropics

Mesh:

Substances:

Year:  2014        PMID: 24957738     DOI: 10.1016/j.euroneuro.2014.05.004

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  5 in total

1.  Haptoglobin in ultra-high risk of psychosis - Findings from the longitudinal youth at risk study (LYRIKS).

Authors:  Jie Yin Yee; Si Qing Chow; Keane Lim; Wilson Goh; Judy Sng; Tih-Shin Lee; Jimmy Lee
Journal:  Brain Behav Immun Health       Date:  2022-06-12

2.  Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75NTR Ligand LM11A-31.

Authors:  Danielle A Simmons; Brian D Mills; Robert R Butler Iii; Jason Kuan; Tyne L M McHugh; Carolyn Akers; James Zhou; Wassim Syriani; Maged Grouban; Michael Zeineh; Frank M Longo
Journal:  Neurotherapeutics       Date:  2021-03-30       Impact factor: 7.620

Review 3.  Disordered Decision Making: A Cognitive Framework for Apathy and Impulsivity in Huntington's Disease.

Authors:  Lee-Anne Morris; Claire O'Callaghan; Campbell Le Heron
Journal:  Mov Disord       Date:  2022-05-02       Impact factor: 9.698

4.  The Spectrum of Psychiatric Pathology in a Patient with Genetically Verified Huntington's Disease.

Authors:  Samir Alkabie; Daljinder Singh; Amy Hernandez; Rhaisa Dumenigo
Journal:  Case Rep Psychiatry       Date:  2015-09-16

Review 5.  A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.

Authors:  Edina Silajdžić; Maria Björkqvist
Journal:  J Huntingtons Dis       Date:  2018
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.